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Abstract 
Background: BST2 inhibits HIV-1 release by tethering nascent virions to the surface of infected cells. HIV-1 Vpu 
overcomes this restriction by removing BST2 from viral budding sites via BST2 intracellular trapping and sequestration, 
surface downregulation and/or displacement mechanisms. Vpu is composed of a short luminal tail, a transmembrane 
domain (TMD) and a cytoplasmic hinge region that is followed by two helices. BST2 counteraction relies on the ability 
of Vpu to physically bind BST2 through TMD interactions and recruit the clathrin-dependent trafficking machinery 
via a canonical acidic di-leucine signalling motif within the helix-2 of Vpu. The highly conserved Vpu transmembrane-
proximal hinge region encompasses residues that resemble an acidic leucine-based trafficking motif, whose func-
tional roles are currently ill-defined. In this study, we investigated the contribution of these residues towards Vpu-
mediated BST2 antagonism.
Results: We show that while these conserved residues have no intrinsic activity on the cellular distribution of Vpu in 
the absence of BST2, they regulate the ability of Vpu to bind to BST2 and, consequently, govern both BST2-dependent 
trafficking properties of the protein as well as its co-localization with BST2. Moreover, these residues, particularly a 
glutamic acid residue positioned immediately following the TMD, are a determinant not only for efficient targeting 
of BST2, but also binding and degradation of CD4, another host membrane protein targeted by Vpu. Mechanistically, 
our data are consistent with a role of these residues in the maintenance of the Vpu TMD conformational configuration 
such that interactions with membrane-associated host targets are favoured.
Conclusions: Altogether, this work demonstrates an important regulatory role of the transmembrane-proximal Vpu 
hinge region residues towards enabling the protein to efficiently engage its target host proteins. Thus, this highly 
conserved, cytosolic Vpu hinge region may represent an attractive target for the development of anti-Vpu inhibitors.
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Background
BST2 (also referred to as Tetherin, CD317 or HM1.24) is 
a type I interferon (IFN-I)-induced membrane-associated 
restriction factor that inhibits HIV-1 release by directly 
cross-linking nascent virions to the surface of infected 
cells [1, 2]. Structurally, BST2 consists of a short N-termi-
nal cytosolic domain, a transmembrane domain (TMD), 
followed by a coiled-coil ectodomain and a C-terminal 
glycosylphosphatidylinisotol (GPI) anchor. Tethering of 
virions results from insertion of one of the membrane 
anchors, preferentially the GPI anchor, into a budding 
virus particle while the other remains inserted into the 
host cell membrane [3]. In order to counteract BST2-
mediated virion tethering, HIV-1 utilizes viral protein U 
(Vpu), a small membrane associated accessory protein that 
is also present in other related SIVs, but not in HIV-2 [4, 
5]. Structurally, Vpu comprises a short luminal N-terminal 
tail, a TMD and a cytoplasmic domain that contains two 
helices separated by a linker region bearing two casein 
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kinase II serine target sites. Phosphorylation of these ser-
ine residues (S52, S56) mediate recruitment of the β-TrCP2 
subunit of the Skp1-Cullin1-F-Box (SCFβ-TrCP2) E3 ubiqui-
tin ligase [6, 7]. A short, flexible hinge region connects the 
TMD and the cytoplasmic domain. Maintenance of proper 
structural elements of Vpu, such as the TMD, is important 
for the ability of the protein to target BST2 as well as an 
array of other host factors, including CD4, NK-T-B-anti-
gen (NTB-A), Polio virus receptor (PVR), sodium-coupled 
neutral amino acid transporter (SNAT1) and the C–C 
chemokine receptor-7 (CCR7) [8–13].
Vpu counteracts BST2 antiviral activity by mediating 
removal of BST2 from virus budding sites via intracel-
lular trapping and sequestration, surface downregulation 
and/or displacement mechanisms [1, 2, 14–16]. A direct 
interaction between Vpu and BST2, which occurs via 
their respective TMDs, is critical for BST2 antago-
nism [9, 16, 17]. The interaction requires a Vpu A10xxx-
A14xxxA18xxxW22 hydrophobic TMD interface, as well as 
several other residues within the TMD [9, 16, 17]. This 
physical association, which is believed to occur in the 
endoplasmic reticulum (ER) and/or the trans-Golgi net-
work (TGN), traps both newly synthesized and recycling 
BST2 within intracellular compartments including the 
TGN [14, 15, 18–20].
BST2 antagonism is closely linked to cellular distri-
bution of Vpu, and is reliant on hijacking of the host 
clathrin-dependent trafficking machinery [18, 21, 22]. A 
canonical acidic di-leucine (ExxxLV) sorting motif within 
the second helix of Vpu from Clade B (VpuB) of the M 
group of HIV-1 (HIV-1M) facilitates recruitment of clath-
rin adaptor protein complexes (AP-1 and AP-2), leading 
to formation of ternary Vpu–BST2–AP complexes [16, 
21, 22]. In addition to the sorting signal, recruitment of 
AP cofactors requires the interaction between Vpu and 
BST2, as well as phosphorylation of Vpu, both of which 
are believed to modulate conformational changes that 
promote interaction with AP complexes. Moreover, a 
dual tyrosine-based motif within the cytoplasmic tail of 
BST2 as well as the Vpu first helix, which forms non-
canonical contacts with AP complexes, are also necessary 
[21, 22]. The Vpu di-leucine sorting motif targets BST2 to 
a yet-to-be-specifically defined endosomal compartment 
that is incompatible with transit of Vpu–BST2 com-
plexes to the cell surface, and is also required for exclu-
sion or lateral displacement of BST2 from viral assembly 
sites [16, 20, 23]. These actively sequestered Vpu–BST2 
complexes are ultimately targeted for ESCRT-mediated 
endo-lysosomal degradation following BST2 polyubiqui-
tination by SCFβ-TrCP2 [24–26]. BST2 degradation, how-
ever, is generally dissociable from enhancement of virion 
release, especially in conditions of low BST2 expression 
levels [22].
Interestingly, even though the VpuB helix-2 di-leucine 
sorting signal drives the first step of BST2 counterac-
tion, it is not conserved across all Vpu variants, as is most 
notable in Vpu variants from HIV-1M clades C (VpuC) 
and F. In these variants, curiously, an equivalent puta-
tive acidic di-leucine motif occurs within the transmem-
brane-proximal hinge region of the protein. Intriguingly, 
in addition to the VpuB helix-2 di-leucine signal, there 
exists a putative acidic di-leucine motif (ExxxIL) within 
the transmembrane-proximal hinge region. Therefore, 
based on the canonical sequence of acidic di-leucine 
motifs (D/ExxxLL/I/V/M) [27], VpuB has an optimal 
helix-2 signal while the hinge region putative motif would 
be predicted sub-optimal. Noteworthy, the membrane-
proximal VpuB ExxxIL and membrane-distal ExxxLV 
mirror the major histocompatibility complex class II-
associated invariant chain (CD74) membrane-proximal 
ExxxML and membrane-distal DxxxLI acidic di-leucine-
based signals that are independently sufficient to recruit 
AP cofactors and target the transmembrane protein to 
endo-lysosomal compartments [28, 29].
Even though not optimal, there are positions within 
the VpuB transmembrane-proximal hinge region puta-
tive motif that are highly conserved, raising the possibil-
ity that the hinge region contributes to BST2 antagonism 
either by modulating Vpu trafficking, BST2 sequestration 
or through some other mechanism. To date, it is unclear 
whether this putative di-leucine motif plays any func-
tional role. As well, the overall roles of the transmem-
brane-proximal hinge region within which the putative 
motif occurs are still ill-elucidated. As such, we set out 
to investigate the role of the VpuB hinge region residues, 
encompassing the putative sorting signal, towards Vpu-
mediated BST2 antagonism. Additionally, considering 
the importance of the structural configuration of Vpu 
for targeting both BST2 and its other host protein target 
CD4, as well as the roles of disordered regions in modu-
lating structural orientation or affording structural plas-
ticity that facilitates interaction with target proteins, we 
further examined whether these conserved hinge region 
residues orient Vpu in such a way that binding to BST2 
and CD4 is favoured.
In this study, we show that while the putative sorting 
motif within the transmembrane-proximal hinge region 
of Vpu does not influence the cellular localization of the 
protein in the absence of BST2, mutations of highly con-
served residues within this region affect the subcellular 
distribution of Vpu and its co-localization with BST2 
in BST2-expressing cells. We further show that these 
residues allow not only for optimal BST2 binding and 
counteraction but also for efficient CD4 interaction and 
degradation, suggesting a role of the transmembrane-
proximal hinge region residues in properly positioning 
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the Vpu TMD to efficiently engage its target host pro-
teins. By demonstrating an important regulatory role 
of the transmembrane-proximal Vpu hinge region resi-
dues in BST2 binding, our study underscores the criti-
cal link between efficient binding of Vpu to BST2 and 
optimal trafficking of Vpu–BST2 complexes to endo-lys-
osomal compartments for sequestration and ultimately 
degradation.
Results
Highly conserved transmembrane‑proximal hinge region 
residues influence Vpu subcellular distribution in a 
BST2‑dependent manner
In order to investigate the involvement of Vpu mem-
brane-proximal hinge region residues (28EYRKIL33) 
in Vpu-mediated BST2 antagonism, we first evaluated 
their roles in governing Vpu cellular localization. Con-
sidering that in active di-leucine sorting motifs the glu-
tamic acid (E) and leucine (L) residue positions are 
critical for activity, we generated provirus-based Vpu 
mutants that would allow for an assessment of whether 
the hinge region E28 and L33 residues modulate Vpu 
trafficking. These included mutants bearing mutations 
within the hinge region (28AYRKIA33, E28A/L33A), 
the second helix sorting signal (59KLSAFV63, E59K/
L63F) while preserving the Env sequence, or both regions 
(E28A/L33A-E59K/L63F) (Fig.  1a). A Vpu A10L/A14L/
A18L (Vpu-AAA) mutant, which is defective for BST2 
interaction [9] was also included. Given the functional 
importance of Vpu accumulation within TGN compart-
ments [14, 18, 20], we analysed the TGN distribution 
of the mutants in HeLa cells transfected with provirus 
plasmids expressing either wildtype (WT) Vpu or the 
various mutants. As previously reported [9, 18, 20], our 
confocal microscopy data revealed a preferential accu-
mulation of WT Vpu in the TGN, as determined by 
the co-staining of Vpu with the TGN marker TGN46 
(Fig.  1b–d). Importantly, the localization of the E28A/
L33A mutant within the TGN was significantly reduced 
[Pearson correlation coefficient (PCC)  =  0.54] rela-
tive to WT Vpu (PCC = 0.65) in these BST2-expressing 
cells. A corresponding two-fold increase in the percent-
age of Vpu distributing beyond the TGN was observed 
(16% for WT Vpu versus 35% for E28A/L33A) (Fig. 1d). 
Indeed, a redistribution of the mutant protein, albeit to 
varying extents, could be detected in punctuate struc-
tures beyond the TGN (see representative panels 1 and 
2, Fig.  1b). An even greater reduction in TGN distribu-
tion was observed for both the E59K/L63F and E28A/
L33A-E59K/L63F mutants (PCC  =  0.43), in agreement 
with the increases in percentages of Vpu occurring 
beyond the TGN (52 and 54%, respectively) (Fig. 1b–d). 
Phenotypically, the E59K/L63F and E28A/L33A-E59K/
L63F mutants redistributed towards the periphery in a 
comparable manner (Fig.  1b–d), indicating that muta-
tion of the putative sorting motif in the hinge region did 
not augment the Vpu localization defect. Noteworthy, the 
accumulation of the Vpu-AAA mutant within TGN46-
positive perinuclear compartments was comparable to 
WT Vpu (Fig. 1b–d). Of particular importance, none of 
the mutants showed any intrinsic defects in their TGN 
abundance following shRNA-mediated depletion of BST2 
in HeLa cells (Fig.  2a, b and Additional file  1: Fig. S1), 
emphasizing that their differential cellular distribution is 
BST2-dependent. The fact that the BST2-binding defec-
tive Vpu mutant, Vpu-AAA, remains localized within the 
TGN as well as Vpu WT in the presence of BST2 (Fig. 1a, 
b) suggests that the Vpu redistributed outside the TGN 
likely represents Vpu whose trafficking properties are 
BST2-dependent.
Given the BST2-dependent cellular distribution of the 
mutants, we next assessed the extent of their co-localiza-
tion with BST2. Our data indicate that WT Vpu, which 
can efficiently bind, sequester and mediate degradation 
of BST2, co-localizes extensively with the restriction fac-
tor essentially within a perinuclear region. Interestingly, 
in the presence of the BST2 binding impaired Vpu-AAA 
mutant, BST2 subcellular distribution was altered with 
an increased localization outside the perinuclear region 
where co-localization with Vpu-AAA was minimal, high-
lighting that BST2 trafficking is influenced by forma-
tion of BST2 complexes (Fig.  3a, b). Given the reduced 
BST2 binding capacity of the Vpu-AAA mutant, its 
perinuclear co-localization with BST2 likely represents 
a mere overlap in staining resulting from the primary 
localization of both proteins in the TGN (Fig. 1a). Inter-
estingly, the E28A/L33A mutant showed a statistically 
significant reduction in the extent of co-localization with 
BST2 compared to WT Vpu, in a large part because of 
a reduced co-localization outside the perinuclear region 
where most of the co-staining was detected (Fig. 3a, b). 
Relative to WT Vpu, the E59K/L63F mutant revealed 
an overall stronger co-localization with BST2 both out-
side and in a perinuclear region, most likely due to lack 
of degradation of Vpu–BST2 complexes in the case of 
this mutant (Additional file  1: Fig. S1). Importantly, the 
extent of BST2 co-localization of E28A/L33A-E59K/L63F 
was lower compared to the E59K/L63F mutant, even 
though both E59K/L63F and E28A/L33A-E59K/L63F do 
not mediate BST2 degradation (Additional file 1: Fig. S1; 
compare the levels of BST2 in the presence of Vpu E59K/
L63F or E28A/L33A-E59K/L63F with those in the pres-
ence of the Vpu S52/56D mutant, which is unable to 
degrade BST2).
Taken together, our immuno-localization data indicate 
that the Vpu hinge region residues E28 and L33, which 
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are part of a putative acidic di-leucine sorting motif, 
influence the BST2-dependent cellular distribution of 
Vpu beyond the TGN as well as the efficient co-locali-
zation of the protein with BST2. Moreover, the fact that 
mutations in the membrane-proximal hinge region motif 
did not augment the Vpu localization defect resulting 
from alterations of the second helix di-leucine motif, sug-
gests a potential functional dependence between these 
two motifs.
Vpu hinge region E28/L33 residues modulate the ability 
of Vpu to antagonize BST2
To test if the differential cellular distribution of the Vpu 
mutants has any functional consequences, we assessed 
their capabilities to downregulate surface BST2 as well 
as to enhance release of viral particles from transfected 
HeLa cells. Compared to WT provirus, a Vpu-deficient 
(dU) provirus was impaired in its surface BST2 down-
regulation function, as previously reported [2, 14, 24] 
(Fig.  4a). Meanwhile, the E28A/L33A mutant was mod-
erately, albeit significantly, attenuated for BST2 down-
regulation (Fig.  4a, b). In line with earlier reports [20], 
the E59K/L63F mutation drastically reduced the extent 
of Vpu-mediated BST2 cell surface downregulation. Of 
particular note, simultaneously mutating both regions 
(E28A/L33A-E59K/L63F) yielded a cumulative defect on 
surface BST2 downregulation. In terms of BST2 antag-
onism, as measured by the ability of Vpu to enhance 
release of nascent virions, the dU mutant was unable to 
counteract BST2 (Fig. 4c, d). Most importantly, the abil-
ity of the E28A/L33A mutant to promote virus release 
was significantly attenuated. Consistent with the BST2 
downregulation phenotype, the E59K/L63F mutant gave 
an even more pronounced attenuation. Yet again, the 
E28A/L33A-E59K/L63F mutant displayed a cumulative 
effect of the two mutated regions, giving a phenotype 
that is slightly higher to that of dU. It is worth mention-
ing that the E28A/L33A mutant was still able to medi-
ate some BST2 degradation, albeit to a lesser extent than 
the WT Vpu (Additional file 1: Fig. S1), unlike the E59K/
L63F, E28A/L33A-E59K/L63F and β-TrCP binding-defi-
cient S52/56D mutants that were totally defective.
Altogether, our data highlight the significance of the 
conserved hinge region E28/L33 residues towards over-
coming BST2 restriction. Of note, their contribution to 
BST2 antagonism is additive with that of the second helix 
di-leucine sorting signal, suggesting that they act at dif-
ferent stages of the counteraction.
Vpu E28/L33 residues are important for binding to BST2
Having shown the defect of these hinge region residues 
on BST2 antagonism and co-localization, we next evalu-
ated the ability of the E28A/L33A mutant to interact with 
BST2. Towards this, we performed co-immunoprecip-
itation (Co-IP) assays in which we co-transfected pro-
viral plasmids expressing the appropriate Vpu mutants 
together with a BST2 expressor into HEK293T cells, and 
pulled down Vpu using anti-BST2 antibodies (Abs). As 
shown in Fig.  5a, whereas WT Vpu and S52/56D were 
efficiently pulled down (lanes 3 and 7), there was no 
enrichment for a Vpu-AAA mutant known to be defec-
tive for BST2 interaction (lane 8), in accordance with the 
importance of the TMD for binding to BST2 [9]. Impor-
tantly, while the E59K/L63F mutant was efficiently pulled 
down (compared to the WT) in these assays (lanes 3 
and 5), the E28A/L33A mutant was significantly attenu-
ated for binding to BST2 (compare lane 4 with lane 3). 
A largely comparable binding defect was observed with 
the E28A/L33A-E59K/L63F mutant (compare lane 6 
with lanes 3 and 5). The binding defect of the E28A/
L33A mutant was independent of the degradation of the 
Vpu–BST2 complexes as it could not be rescued when 
the assay was performed using a BST2 expressor encod-
ing for a short isoform of BST2 that contains the TMD 
involved in Vpu binding but is insensitive to Vpu-medi-
ated downregulation and degradation (Fig.  5b) [30, 31]. 
Thus, our data indicate that the hinge region E28/L33 
residues are important for the ability of Vpu to optimally 
interact with BST2, a condition that is necessary for 
Vpu-mediated BST2 counteraction. These results further 
(See figure on previous page.) 
Fig. 1 Membrane-proximal, hinge region E28/L33 residues are important for Vpu localization in the TGN. a Schematic representation of the struc-
tural domains and the sequence of the prototypical HIV-1 clade B NL4-3 Vpu (NL4-3, WT). Shown also are sequences of various Vpu mutants used 
in the study. b Intracellular localization of the Vpu mutants. HeLa cells were transfected with proviral plasmids encoding either WT Vpu or one of 
E28A/L33A, E59K/L63F, E28A/L33A-E59K/L63F and A10L/A14L/A18L Vpu mutants and were co-stained with anti-TGN46 (red, for TGN) and anti-Vpu 
(green) Abs as well as with DAPI (grey, for nucleus). Shown are representative confocal microscopy pictures for each of the Vpu mutants, with two 
prototypical patterns (1&2) of localization observed with the E28A/L33A mutant. c, d Quantification of the co-staining of anti-Vpu and anti-TGN46 
Abs obtained from at least 50 distinct transfected cells per mutant. Shown are Pearson correlation coefficients (PCC) for each mutant (c) as well as 
Vpu distribution beyond the TGN (d). The percentage of Vpu distributing beyond the TGN was determined by calculating the ratio of the intensity 
of Vpu not co-staining with TGN versus total Vpu intensity in transfected cells. The white bars in B represent a distance of 10 µm and the horizontal 
lines (c, d) represent mean values of the PCC (c) and percentage of Vpu distributing beyond the TGN (d). Statistical analyses were performed using 
Mann–Whitney test
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Fig. 2 E28/L33 residues have no intrinsic activity on Vpu cellular distribution in the absence of BST2. a Intracellular localization of Vpu mutants 
in HeLa cells depleted of BST2 (SH-BST2, treated with shRNA against BST2) or not (NT-BST2, treated with non-targeting shRNA). Transfected cells 
were co-stained with anti-TGN46 (red, for TGN) and anti-Vpu (green) Abs as well as with DAPI (grey, for nucleus). Shown are representative confocal 
microscopy pictures for each of the Vpu mutants. The white bars represent a distance of 10 µm. b Quantification of the co-staining of anti-Vpu and 
anti-TGN46 Abs obtained from at least 50 distinct transfected cells per mutant. Shown are PCC values from each mutant. The horizontal lines repre-
sent the mean PCC. Statistical analyses were performed using Mann–Whitney test
Page 7 of 18Lukhele and Cohen  Retrovirology  (2017) 14:18 
Fig. 3 Hinge region E28/L33 residues are important for Vpu co-localization with BST2. a Representative pictures showing extent of co-localization 
of Vpu mutants with endogenous BST2 in HeLa cells as determined by the co-staining of anti-Vpu (green) and anti-BST2 (red) Abs following intracel-
lular staining for both Vpu and BST2. b PCC values obtained from quantification of co-stainings of anti-Vpu and anti-BST2 Abs from at least 40 dis-
tinct transfected cells. The white bars in panel A represent a distance of 10 µm and the horizontal lines in panel B represent the mean PCC. Statistical 
analyses were performed using Mann–Whitney test
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suggest that the attenuated binding of E28A/L33A to 
BST2 could be responsible for the observed cellular local-
ization and BST2 co-localization defects (Figs.  1, 3). In 
order to test this, we introduced mutations in Vpu TMD 
residues (A14L, A18L and A10L/A18L) that are relevant 
for binding to BST2 and correlated their binding strength 
Fig. 4 Conserved residues within the membrane-proximal hinge region of Vpu are important for BST2 counteraction. a A flow cytometry repre-
sentative overlay showing the amount of surface BST2 following transfections of HeLa cells with either WT Vpu or the indicated Vpu mutants. Mean 
fluorescence intensity (MFI) values are indicated on the right. b A compilation of four independent experiments showing the extent of surface BST2 
downregulation as determined by subtracting BST2 MFI values obtained from transfected cells (GFP+) from those in non-transfected cells (GFP−), 
and expressed as a percentage relative to the efficiency of BST2 downregulation obtained from WT Vpu, which in turn was arbitrarily set at 100%. 
c, d Efficiency of virus particle release following transfection of HeLa cells with provirus plasmids encoding WT Vpu and the indicated mutants. c A 
representative Western blot showing the amount of virion-associated p24 released into the supernatant (virion) and Gag products (p24 and p55) 
in the cell lysate. d A summary of quantifications of released virus particles by densitometric analyses of the intensity of Gag-related band signals 
from the Western blots from four different experiments. The efficiency of virus release was determined by calculating the ratio of virion-associated 
p24 released into the supernatant versus total Gag (cell- and virus-associated), and is expressed as a percentage of the release efficiency of the WT 
provirus, which in turn was set at 100%. For both (b) and (d), the error bars represent standard deviation (SD). Statistical analyses were performed 
using a two-way ANOVA, Tukey’s multiple comparison test
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(or lack thereof ) to their cellular distribution. While the 
Vpu A14L was severely impaired for both BST2 binding 
and counteraction (resembling the Vpu-AAA mutant), 
the A18L and A10L/A18L gave intermediate BST2 
binding and BST2 antagonistic phenotypes (Additional 
file 2: Fig S2 and Fig. 6a). In fact, their BST2 binding and 
functional profiles were comparable to the E28A/L33A 
mutant. Very importantly, the Vpu A18L and A10L/
A18L mutants distributed beyond the TGN in a man-
ner mirroring that obtained with the E28A/L33A mutant 
(Fig. 6b–d). Thus, the Vpu–BST2 binding affinity modu-
lates the cellular distribution of Vpu. Taken together, the 
E28/L33 residues are a determinant for interaction with 
BST2, which in turn regulates both the cellular distribu-
tion and functional properties of the protein. 
The E28/L33 residues are important for CD4 binding 
and degradation
Efficient interaction between Vpu and BST2 is depend-
ent on both the identities of the amino acids and the 
proper structures of their respective TMD helices [9, 17, 
32]. To ensure access to the BST2 TMD, the Vpu TMD 
A10xxxA14xxxA18xxxW22 interacting interface orients 
such that it aligns with the bulky residues on the BST2 
TMD, facing the opposite direction of the Vpu cytoplas-
mic domain [17, 32]. Moreover, the TMDs of both pro-
teins have to adopt optimal tilt angles that are permissive 
to a direct interaction [17, 33]. Along this line, correla-
tions between the extent of Vpu binding and tilt angles 
have since been reported [33]. As such, our data raise the 
possibility that the E28A/L33A mutation perturbs the 
structural orientation of the Vpu TMD. To test this, we 
evaluated the ability of the E28A/L33A mutant to inter-
act with another host membrane target protein of Vpu, 
the CD4 viral receptor, which is intercepted in the endo-
plasmic reticulum (ER) prior to trafficking to more distal 
cellular compartments and that requires an intact Vpu 
TMD. Vpu mediates the degradation of CD4 by connect-
ing the viral receptor to components of the ER-associated 
protein degradation (ERAD) pathway through a process 
that requires Vpu-CD4 binding via both the TMD and 
first helix of Vpu, as well as recruitment of the SCFβ-TrCP 
E3 ligase complex [7, 8, 34–36].
First, to assess the ability of the Vpu mutants to 
degrade CD4, HEK293T cells were co-transfected with 
a CD4 expressor and proviruses expressing WT Vpu or 
Fig. 5 E28/L33 residues are important for binding of Vpu to BST2. a HEK293T cells were co-transfected with a proviral construct encoding WT 
Vpu or the indicated Vpu mutants and a BST2 expressor. Co-IP assays were then performed using an anti-BST2 Ab to pull down Vpu. Shown is a 
representative Western blot indicating the expression levels of proteins of interest in both the input lysate [actin (loading control), p55 (transfection 
control), BST2 and Vpu] and the immunoprecipitated fraction (BST2 and Vpu). b Co-IP following co-transfection of HEK293T cells with a proviral con-
struct encoding WT Vpu or the indicated Vpu mutant and an expressor encoding for the short isoform of BST2 that contains the TMD involved in 
Vpu binding but is insensitive to Vpu-mediated degradation. Below each blot is the extent of BST2 binding of each Vpu mutant, relative to WT Vpu 
(set at 100%). For each condition, BST2 binding efficiency was determined from the ratio obtained from densitometric analyses of the intensities of 
Vpu- and BST2-related band signals in the immunoprecipitated fractions
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Vpu mutants (dU, E28A/L33A or S52/56D), and CD4 
steady-state levels were evaluated by Western blot-
ting. While WT Vpu was efficient at mediating CD4 
degradation relative to dU, the S52/56D mutant was sig-
nificantly impaired for this function, owing to the fact 
that it is defective for β-TrCP recruitment (Fig.  7a–c). 
Fig. 6 Impaired BST2-binding Vpu TMD mutants display defects in cellular distribution. a Enhancement of virus release by Vpu TMD and E28A/
L33A mutants. A representative Western blot showing the amount of virion-associated p24 released into the supernatant (virion) and Gag products 
(p24 and p55) in the cell lysate. Below the blot are values indicating the efficiency of virus release (quantified and expressed as mentioned in Fig. 4 
legend). b–d Vpu TMD mutants are defective for TGN localization. b HeLa cells transfected with either WT, E28AL/L33A, A18L or A10L/A18L Vpu 
mutants were co-stained with anti-TGN46 (red, for TGN) and anti-Vpu (green) Abs as well as with DAPI (grey, for nucleus). Shown are representa-
tive confocal microscopy pictures for each of the Vpu mutants. c, d Quantification of the co-staining of anti-Vpu and anti-TGN46 Abs obtained 
from at least 50 distinct transfected cells per mutant. Shown are Pearson correlation coefficients (PCC) for each mutant (c) as well as Vpu distribu-
tion beyond the TGN (d). The percentage of Vpu distributing beyond the TGN was determined by calculating the ratio of the intensity of Vpu not 
co-staining with TGN versus total Vpu intensity in transfected cells. The white bars in B represent a distance of 10 µm and the horizontal lines (c, d) 
represent mean values of the PCC (c) and percentage of Vpu distributing beyond the TGN (d). Statistical analyses were performed using Mann–
Whitney test
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Importantly, the E28A/L33A mutant was significantly 
attenuated for CD4 degradation, yet retained the ability 
to efficiently interact with β-TrCP (Fig.  7a–c). We then 
asked whether the E28A/L33A mutant was still able to 
bind CD4. Towards this, we co-transfected HEK293T 
cells with a CD4 expressor and the proviral Vpu mutants, 
and performed Co-IP assays using anti-CD4 Abs to pull 
down Vpu. Whereas WT Vpu and S52/56D were effi-
ciently pulled down, the E28A/L33A mutant was not, 
indicating that the E28/L33 residues contribute to the 
interaction of Vpu with CD4 (Fig. 7d).
Taken together with the BST2 binding data, the results 
demonstrate that the E28/L33 residues are essential for 
optimal binding to both BST2 and CD4.
E28 is a determinant for both Vpu‑mediated CD4 
degradation and BST2 antagonism
We next wanted to delineate the contributions of the 
E28/L33 residues towards the observed functional and 
binding phenotypes. Considering the proximity of the 
E28 residue to the functionally important TMD, as well 
as the fact that it is highly conserved across Vpu variants 
Fig. 7 E28A/L33A mutation affects the ability of Vpu to target CD4. a, b E28A/L33A is attenuated for CD4 degradation. HEK293T cells were co-
transfected with a proviral construct encoding WT Vpu or the indicated Vpu mutant proviruses and a CD4 expressor, and probed for the steady state 
levels of CD4. a Shown is a representative Western blot. b A summary of the densitometric quantifications of the steady-state CD4 levels from inde-
pendent experiments, together with the SD (n = 7). Statistical analysis was performed using a two-way ANOVA, Tukey’s multiple comparison test. 
c E28A/L33A is efficient at recruiting β-TrCP. HEK293T cells were co-transfected with the indicated proviral constructs and a myc-tagged β-TrCP2 
expressor. A Co-IP assay was performed using anti-myc Abs to analyze β-TrCP complexes for the presence of Vpu. d E28A/L33A is attenuated for 
CD4 binding. HEK293T cells were co-transfected as in (a), and a Co-IP assay performed using anti-CD4 Abs to pull down Vpu. Shown is a representa-
tive Western blot indicating the amount of Vpu in the lysate and pulled down fractions in each case. The asterisk denotes an Ab-related band
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(Fig.  8a), we hypothesized that it is primarily the glu-
tamate that acts as a membrane anchor for this TMD 
region. Focusing on the glutamate, we introduced E28A, 
E28D and E28Q point mutations in order to discern 
whether the charge, polarity and/or intrinsic structural 
elements are essential for targeting CD4 and/or BST2. 
Noteworthy, the Gln is also found in other variants of 
Vpu, especially those from HIV-1M G subtype [49].
Fig. 8 The conserved glutamic acid residue within the hinge region of Vpu modulates the protein functions. a Logo plots demonstrating the 
amino acid conservation at each position within the 28EYRKIL33 transmembrane-proximal hinge region of Vpu isolates from HIV-1 Clade B (left 
panel) as well as from all HIV-1 clades (right panel) [49]. b, c CD4 degradation mediated by E28 single-point mutants. b A representative Western 
Blot indicating steady state levels of CD4 following co-transfections of HEK293T cells with a CD4 expressor and the indicated proviral constructs. c 
Quantitative densitometric analyses of efficiency of Vpu mutants to degrade CD4 from a compilation of five independent experiments. d, e E28 is 
important for efficient enhancement of virus release in HeLa cells transfected with proviral constructs encoding Vpu single-point mutations. d A 
representative Western blot showing the amount of virion-associated p24 released into the supernatant (virion) and Gag products (p24 and p55) in 
the cell lysate. e A summary of the efficiency of virus release (quantified and expressed as mentioned in Fig. 4 legend) from five different experi-
ments. For both (c) and (e), the error bars represent SD. Statistical analyses were performed using a two-way ANOVA, Tukey’s multiple comparison 
test
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In terms of mediating CD4 degradation, our results 
indicate that whereas both E28D and E28Q mutants 
were comparable to WT Vpu, the E28A mutant was 
significantly defective, suggesting that the E28 posi-
tion can accommodate a polar or semi-conservative 
residue (Fig. 8b, c). In fact, the E28A mutation was suf-
ficient to account for the difference or attenuated phe-
notype observed with the E28A/L33A mutant. For BST2 
antagonism, however, it was particularly interesting 
that all the mutants showed a modest, yet statistically 
significant attenuation compared to WT Vpu (Fig.  8d, 
e). Noteworthy, while the L33 position was previously 
reported to be dispensable for virus release [18], mutat-
ing it in the context of the E28A was necessary in order 
to give the defective phenotype observed with the E28A/
L33A mutant. Similar to their BST2 antagonistic activi-
ties, the single mutants were all attenuated for Vpu-
mediated BST2 degradation (Additional file  3: Fig. S3). 
As such, the data argue that the glutamate residue offers 
some unique intrinsic properties that are important for 
targeting BST2. In line with these observations, E28A 
also displays a reduced binding to BST2 (Fig. 9). Interest-
ingly, this attenuation in BST2 binding appears slightly 
less than that of the E28A/L33A mutant, suggesting that 
the intermediate ability of Vpu E28A to counteract BST2 
correlates with its extent of binding to the restriction 
factor. Altogether, the above observations are consistent 
with a role of the glutamic acid residue in allowing for 
optimal counteraction of BST2 as well as efficient target-
ing and degradation of CD4.
Discussion
In this study, we investigated the contribution of the 
highly conserved transmembrane-proximal hinge region 
(28EYRKIL33) towards Vpu-mediated BST2 antago-
nism. We show that while residues in this region have no 
intrinsic activity on the cellular distribution of Vpu in the 
absence of BST2, they regulate the ability of Vpu to bind 
BST2 and, consequently, govern both BST2-dependent 
trafficking properties of the protein as well as co-locali-
zation with BST2. We further show that these conserved 
residues are important not only for BST2 counteraction 
but also for the capacity of Vpu to efficiently target the 
CD4 viral receptor for degradation in the ER. Ultimately, 
our results reveal that these conserved hinge region resi-
dues are important for the ability of Vpu to optimally 
counteract BST2 and degrade CD4. While mutagenesis 
analysis of conserved residues revealed subtle differences 
regarding the relative importance of these residues for 
BST2 or CD4 targeting, evidence points towards a poten-
tial role of these residues in the maintenance of the Vpu 
TMD conformational configuration such that interac-
tions with membrane-associated host targets, via asso-
ciation between their respective TMDs, are favoured.
Optimal binding of Vpu to BST2 is a critically impor-
tant pre-requisite for antagonism. To date, this exten-
sively characterized direct binding has been shown to 
involve residues within the transmembrane regions of 
both proteins, with no evidence implicating the Vpu 
hinge region residues in said interaction [9, 16, 17]. Our 
finding that the hinge region residues also regulate this 
interaction was therefore unexpected, and highlights 
a previously unappreciated important determinant for 
BST2 binding that occurs beyond the reported TMD 
residues. This binding modulation is likely due to a regu-
latory effect on the conformational integrity of the Vpu 
TMD, as evidenced by the defects in Vpu-mediated 
functions that are dependent on interactions involving 
the TMD. Accordingly, these residues are important for 
targeting BST2 and CD4, and could conceivably play a 
role in the interaction with other membrane-associated 
host targets of Vpu including NTB-A, PVR, SNAT1 and 
CCR7. Preservation of both secondary and tertiary struc-
tures, as well as positioning of the TMD likely enable 
interactions with these target proteins. The conforma-
tional integrity of the Vpu TMD is indeed essential for 
optimal biological activity, as recently demonstrated by 
the positive correlation between alterations in tilt angles 
Fig. 9 E28 residue is a key modulator of binding of Vpu to BST2. 
Co-IP following co-transfection of HEK293T cells with a proviral con-
struct encoding WT Vpu, E28A/L33A or E28A Vpu mutants and a BST2 
expressor. Below the blot is the extent of BST2 binding of each Vpu 
mutant, relative to WT Vpu (set at 100%). BST2 binding efficiency was 
determined as indicated in Fig. 5 legend
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and attenuation in BST2 antagonism observed in Vpu 
TMD mutants [33]. Similarly, altered tilt angles of BST2 
TMD mutants confined within lipid bilayers desensitized 
them to the antagonistic activity of Vpu, yet they retained 
an intrinsic ability to interact with Vpu in solution [17]. 
Furthermore, nuclear magnetic resonance data on the 
direct helix–helix interaction between Vpu and BST2 
TMDs demonstrate the need for appropriate alignment 
of the Vpu interacting interface in order to directly con-
tact the bulky BST2 TMD residues that likely fit between 
the alanine-based interface of the Vpu TMD [17]. Con-
sistently, the Vpu TMD interface faces away from the 
cytoplasmic domain of the protein, ensuring accessibility 
to its binding partners [32].
The evidence presented herein implying a contribution 
of the Vpu hinge region residues, especially the glutamate 
at the TMD-cytoplasmic interface, towards anchoring 
the TMD is in accordance with previous findings demon-
strating a modulatory function of a similarly positioned 
glutamate residue in the conformational positioning of a 
model poly-Leu TMD helix [37]. Mutating the glutamate 
residue is believed to abrogate its role of linking the TMD 
hydrophobic segment to the aqueous phase, resulting in 
a mismatch between the hydrophobic helix relative to 
the length of phospholipids in the bilayer and, ultimately, 
altered TMD tilt angles [38, 39]. Interestingly, glutamate 
residues flanking TMDs of bacteriorhodopsin were also 
shown to modulate the conformational configurations of 
the TMDs, including the mobility of Ala and Val TMD 
residues [40, 41]. More interesting still, and corroborat-
ing our findings herein, these studies also document the 
uniqueness of the glutamate intrinsic properties, as it 
could not be substituted even with a semi-conservative 
glutamine residue, [40, 41]. This likely reflects the supe-
rior capability of the Vpu Glu to form stabilizing inter-
actions with the positive residues R30/K31/R34 via 
hydrogen bonds or salt bridges [42, 43].
The interaction of Vpu and BST2 mediates the recruit-
ment of clathrin AP complexes that govern BST2 intra-
cellular sequestration, degradation, endocytosis and 
displacement from viral assembly sites [21, 22]. Thus, 
by disrupting Vpu interaction with BST2, mutations 
of conserved residues of the hinge region are likely to 
affect the recruitment of AP via the di-leucine trafficking 
motif in the second helix of Vpu [22]. Indeed, the aber-
rant BST2-dependent cellular distribution of the E28A/
L33A mutant is likely a consequence of such a defect, in 
line with the notion that mutations that affect AP recruit-
ment lead to defects in cellular localization only in the 
context of the Vpu–BST2 complex [20, 22]. In fact, the 
extent of BST2 counteraction by the E28A/L33A mutant 
appears to correlate with both its significantly compro-
mised binding phenotype and its slightly altered cellular 
localization in the presence of BST2. Interestingly, the 
altered Vpu localization triggered by the E28A/L33A 
mutant was not found to be additive with the localization 
alteration induced by the second helix di-leucine mutant, 
consistent with the requirement of a Vpu–BST2 physical 
interaction for recruitment of AP proteins [20, 22]. Thus, 
our data support previous results emphasizing the strong 
correlation between Vpu-mediated BST2 antagonism 
and both Vpu–BST2 interaction and Vpu–BST2 complex 
cellular localization.
The functional contribution of the glutamate residue 
is distinct from that mediated by the other hinge region 
residues (28EYRKIL33). While our previous findings 
showed that Y29 was dispensable for BST2 antagonism, 
the R30/K31 residues were found important, yet were 
dispensable for both binding to BST2 and CD4 degrada-
tion [18]. Mechanistically, unlike the E28/L33 residues, 
the R30/K31 residues appear important for the intrinsic 
cellular distribution of Vpu within the TGN [18], imply-
ing that they are unable to efficiently intercept recycling 
and/or newly synthesized BST2. Altogether, therefore, 
these E28/R30/K31/L33 flexible hinge region residues 
play unique, multifaceted functional roles, much like the 
other membrane-distal flexible linker occurring between 
the two alpha helices of Vpu that regulates binding to 
both AP proteins and β-TrCP [6, 7, 22].
Considering the functional importance of the trans-
membrane-proximal hinge region glutamate, it is not 
surprising that this residue is highly conserved across 
HIV-1M Vpu variants. Consistent with our findings 
herein, a recent study reported that only two out of a pool 
of 304 patient-derived Vpu alleles had a lysine substitu-
tion at this position, and were significantly impaired in 
their ability to mediate both BST2 antagonism and sur-
face CD4 downregulation [44]. Intriguingly, in the case of 
Vpu variants with a canonical di-leucine motif within the 
second helix, such as in VpuB, the hinge region residues 
offer some plasticity in that only a single amino acid sub-
stitution would be sufficient to generate an optimal traf-
ficking motif (ExxxIL vs ExxxLL). Along this line, analysis 
of the Los Alamos HIV database reveals that 13% of VpuB 
variants (18) with mutations at critical positions within 
their helix-2 di-leucine motifs (136 out of a total of 1648 
Vpu variants) have optimal putative transmembrane-
proximal hinge region trafficking signals [49]. Indeed, 
while the influence of the hinge region residues on BST2 
binding, and hence Vpu (NL4.3) cellular distribution, is 
consequential, we cannot formally rule out that these 
residues, which are part of a putative acidic di-leucine 
trafficking motif, also contribute directly to Vpu–BST2 
complex trafficking. Future studies aimed at character-
izing the exact compartments into which the mislocal-
ized Vpu (NL4.3) is distributed would be essential in 
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discerning whether these residues play any role in modu-
lating trafficking of the protein in the presence of BST2. 
Nevertheless, there appears to be a selective pressure to 
maintain the glutamate residue at this position in order 
to ensure optimal activity of the TMD as shown herein. 
Of note, in the case of VpuC, the hinge region residues do 
meet the canonical sequence requirements for a di-leu-
cine motif (ExxxLL), whereas the second helix possesses 
a putatively sub-optimal di-leucine motif (ExxxMV). It 
remains to be elucidated whether the hinge region glu-
tamate residue in VpuC contributes towards binding to 
BST2 and/or CD4, and whether it is involved as a part of 
an active trafficking signal.
Conclusions
Overall, this work demonstrates an important regula-
tory role of the Vpu transmembrane-proximal hinge 
region for the ability of the protein to optimally interact 
with its target host factors. As such, it is an important 
determinant for optimal Vpu-mediated BST2 antago-
nism and CD4 degradation, both of which are key for 
viral pathogenesis. Furthermore, considering that this 
domain is highly conserved, occurs within the cytosolic 
region of the protein, and modulates binding to various 
host targets, it may represent an attractive target for the 
development of anti-Vpu inhibitors, unlike the TMD, 




Rabbit sera for pre-immune and anti-Vpu, mouse 
anti-p24 monoclonal and anti-CD4 (OKT4) Abs were 
described previously [18]. Rabbit serum for anti-BST2 
and mouse anti-myc (clone 9E10) Abs used for co-immu-
noprecipitation were also described previously [14]. Poly-
clonal sheep anti-TGN46 and mouse anti-BST2 used in 
confocal microscopy immunostainings were obtained 
from Serotec and Abnova, respectively. Rabbit Abs 
directed against CD4 (Santa Cruz Biotechnology), Myc 
(Sigma) and actin (Sigma) used for Western blot analyses 
were obtained from commercial sources as indicated. All 
secondary Alexa-conjugated immunoglobulin G (IgG) 
Abs used for flow cytometry and confocal microscopy 
were obtained from Life Technologies. Paraformaldehyde 
(PFA) was obtained from Sigma.
Plasmids, cell lines and transfections
Plasmids
WT HIV-1 NL4.3 was obtained through the NIH AIDS 
Reagent Program and a dU provirus plasmid was kindly 
provided by Dr. Klaus Strebel. All Vpu mutants described 
were in the parental NL4.3 provirus genome background, 
and were generated by PCR-based Quick-change site-
directed mutagenesis according to standard protocols 
using cloned Pfu (Agilent). The oligonucleotides used are 
(only the sense strand is shown): E28A 5ʹ-CATAGTAAT
CATAGCATATAGGAAAATATTAAGAC-3ʹ; E28D 5ʹ-C
CATAGTAATCATAGATTATAGGAAAATATTAAGA






GGATGAAGGAGAAGTATCAGCA-3ʹ; A14L 5ʹ- GTA
GCATTAGTAGTATTAATAATAATAGCAATAGTTG






TGTGGTCC-3ʹ. For the E28A/L33A-E59K/L63F mutant, 
sequential mutagenesis was performed using the E59K/
L63F oligonucletides on the E28A/L33A template plas-
mid. The provirus Vpu-AAA mutant was also described 
previously [45], except that the provirus backbone used 
here did not encode GFP. All plasmid constructs were 
confirmed by DNA sequencing. The expression plas-
mids pCR3.1, encoding the short isoform of BST2 [45], 
SVCMV-CD4 [46], and pSVCMV VSV-G encoding the 
vesicular stomatitis virus glycoprotein G (VSV-G) [14] 
were described previously as indicated. The expression 
plasmid for pCR3.1 HA-BST2 gene was kindly provided 
by Dr. Bieniasz [47] while the pcDNA/Myc-His-β-TrCP 
plasmid was obtained from Dr. Richard Benarous [7].
Cell lines HEK293T and HeLa cells were obtained 
from the American Type Culture Collection. Both cell 
types were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM, Wisent) supplemented with 10% fetal 
bovine serum (FBS) and a combination of Penicillin–
Streptomycin antibiotics. HeLa cells depleted of BST2 
were generated by transducing lentiviral vector particles 
encoding shRNA targeting BST2 [48] or, as a control, a 
non-targeting shRNA. The HeLa-TZM-bl cells were 
obtained through the NIH AIDS Reagent Program.
Transfections HEK293T and HeLa cells were seeded 
overnight and transfected using the calcium-phos-
phate method and lipofectamine 2000™ (Invitrogen), 
respectively.
Virus particle release assay
Viral particle release was analyzed by Western blot as 
described previously [14]. The intensity of Gag signal 
was measured by scanning densitometry analyses using 
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ImageJ software (NIH). The ratio of virion-associated 
Gag (p24) signal to cell-associated Gag (p24 and p55) 
was indicative of the viral particle release efficiency. His-
tograms indicate Vpu-specific virus release efficiencies 
following subtraction of any background or non-Vpu spe-
cific effect as determined by the dU control. Vpu-medi-
ated virus release efficiency was normalized to the value 
obtained from HIV-1 WT Vpu cultures, which was arbi-
trarily set at 100%.
BST2 surface staining and flow cytometry
BST2 cell-surface staining was performed on HeLa cells 
co-transfected with proviral constructs expressing the 
indicated mutants together with a GFP expressor plas-
mid for gating purposes. Preparation of cells and flow 
cytometry analysis were described previously [14]. Sur-
face BST2 down-regulation efficiency was determined 
by subtracting BST2 geometric mean fluorescence inten-
sity (MFI) values obtained from GFP-expressing  (trans-
fected cells) cells from BST2 MFI values obtained from 
GFP non-expressing cells. For histograms, the efficiency 
of BST2 downregulation was expressed relative to that 
obtained from HIV-1 WT Vpu cultures, which was arbi-
trarily set at 100%.
Production of VSV‑G pseudotyped HIV‑1 viruses
HEK293T cells were co-transfected with NL4.3 (or 
appropriate mutants) proviral constructs and pSVCMV 
VSV-G as described previously [15]. Forty-eight hours 
post-transfection, supernatants of transfected cells were 
clarified by centrifugation, filtered through a 45-μm filter, 
and pelleted by ultracentrifugation onto a 20% sucrose-
PBS cushion for 2 h at 112,000×g at 4 °C. Concentrated 
viruses were resuspended in DMEM supplemented with 
10% FBS. Viruses were titrated using a standard MAGI 
assay as previously described [14].
Protein steady‑state levels
BST2 degradation
HeLa cells were infected with VSV-G-pseudotyped 
HIV-1 proviruses expressing WT, dU or Vpu mutants 
at an MOI of 1.5 in presence of polybrene. The infection 
medium was replaced four hours post-infection. Forty-
eight hours post-infection, cell lysates were harvested 
and lysed in RIPA-DOC buffer. BST2 steady state levels 
were analyzed by Western blotting as described [14].
CD4 depletion
HEK293T cells were co-transfected with a CD4 expres-
sor and the appropriate proviral plasmids. Following lysis 
at forty-eight hours post-transfection, lysates were sub-
jected to Western blotting and probed for steady-state 
levels of CD4.
Cellular localization and confocal microscopy
Cover-slip seeded BST2-expressing or BST2-depleted 
HeLa cells were transfected with NL4.3 proviral plas-
mids expressing either WT Vpu or the indicated Vpu 
mutants. Twenty-four hours post-transfection, cells 
were fixed for 30  min in 4% PFA and then permeabi-
lized in 0.2% Triton for 5  min. Following washes, per-
meabilized cells were incubated for 2  h at 37  °C in 5% 
milk-PBS containing rabbit anti-Vpu, sheep anti-TGN46 
and/or mouse anti-BST2 Abs as appropriate. The cells 
were then washed and incubated with the appropri-
ate Alexa Fluor-coupled secondary Abs for 45  min 
at room temperature followed by an incubation with 
4′,6-diamidino-2-phenylindole (DAPI) for 5  min also 
at room temperature. All analyses were acquired using 
a 63× Plan Apochromat oil immersion objective on an 
LSM710 Observer Z1 laser scanning confocal micro-
scope (Zeiss). Quantitative analyses were performed 




HEK293T cells were co-transfected with a BST2 expres-
sor plasmid (WT or a short isoform of BST2) together 
with proviral plasmids expressing either WT Vpu or 
indicated mutants. Forty-eight hours post-transfection, 
cells were harvested in PBS/EDTA, centrifuged and 
lysed in CHAPS buffer (50  mM Tris, 100  mM NaCl, 
0.5% CHAPS, pH 7.2) supplemented with a cocktail of 
protease inhibitors (Protease Inhibitors Complete, with 
EDTA). An aliquot of 10% of cell lysate was preserved for 
Western blot loading as “Input” control. Cell lysates were 
then pre-cleared with protein A Sepharose beads coated 
with pre-immune rabbit serum for 1 h at 4 °C. Following 
pre-clearing, the lysates were incubated with rabbit anti-
BST2 specific serum for 3 h at 4 °C, and then precipitated 
using protein A Sepharose beads in a further 3-h incu-
bation at 4 °C. Western blotting was then used to probe 
for presence of Vpu and BST2 in immunoprecipitated 
fractions.
Vpu and CD4 interaction
HEK293T cells were co-transfected with a CD4 express-
ing plasmid and the appropriate proviral plasmids, and 
similar steps were followed as above, except pre-immune 
mouse serum was used for pre-clearing, and mouse anti-
CD4 Abs were used to pull down Vpu.
Vpu and β‑TrCP binding
HEK293T cells were co-transfected with a myc-tagged 
β-TrCP2 expressing plasmid and the appropriate pro-
viral plasmids, and similar Co-IP steps were followed as 
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above, except pre-immune mouse serum was used for 
pre-clearing, and mouse anti-myc Abs were used to pull 
down Vpu.
Statistical analysis
Statistical analyses for confocal microscopy data were 
performed using an unpaired, Mann–Whitney test. All 
other analyses were performed using two-way ANOVA, 
with Tukey’s multiple comparison test. Values were 
considered statistically significant at ‘p’ values of <0.05. 
For all statistical analyses, ****, ***, **, * and ‘ns’ denote 
p  <  0.0001, p  <  0.001, p  <  0.01, p  <  0.05 and p  >  0.05, 
respectively (ns = not significant).
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